Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5212

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5212). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5212 1)

Packaging label for Losartan Potassium 50 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 120 film-coated tablets. Tablets are described as oval-shaped, white/off-white, and scored with specific markings. The label includes manufacturer details from Herbal Labs Limited, Mahabubnagar, India, and storage instructions to keep at controlled temperatures of 68-77°F. Contains various barcodes, NDC 68071-5212-1, and warnings to keep out of reach of children.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Atenolol and Losartan Potassium. The x-axis represents study months, and the y-axis shows the percentage of patients. The graph indicates an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months of study between two treatments: Atenolol and Losartan Potassium. The graph shows lower stroke incidence in patients treated with Losartan Potassium, with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months, and the y-axis shows the percentage of patients.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot chart showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. The chart displays event rates, hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes across different populations categorized by age, gender, race, ISH status, diabetes presence, and history of cardiovascular disease.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over time (in months) between Losartan potassium and placebo groups. The graph shows an increasing trend in events up to 48 months, with Losartan potassium having a lower percentage of events compared to placebo, indicating a risk reduction of 16.1% (p=0.022).*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium, showing its molecular components and arrangement including a chlorinated biphenyl and triazole ring system with potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.